CSPC Pharmaceutical Group Stock Forecast for 2023 - 2025 - 2030

Updated on 03/28/2024

Stock Rating
18
Price Target
HK$9.27
Consensus
Outperform
Upside
54.24%
Analysts
6
Stock Rating
18
Upside
54.24%
Analysts
6
Price Target
HK$9.27

CSPC Pharmaceutical Group Stock Forecast and Price Target

If the average 2024 price target of HK$9.27 recently set by six prominent experts for CSPC Pharmaceutical Group is met, there would be a potential upside of approximately 54.24% from the last closing price in March, 2024. The high estimate is HK$13.00, and the low is HK$5.90. If you want to invest in 1093 stock, you might also want to take a look at how its competitors are doing.

HK$9.27

54.24% Upside

Outperform
Outperform

CSPC Pharmaceutical Group Fair Value Forecast for 2023 - 2025 - 2030

In the last four years, CSPC Pharmaceutical Group has seen a decline in its Price, from HK$7.38 to HK$0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of HK$8.66, which would mean an increase of 100.00%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Fair Value will grow at a rate of 100.00%.

2024 Fair Value Forecast
HK$8.66
2025 Fair Value Forecast
HK$9.51
2026 Fair Value Forecast
HK$7.52
2027 Fair Value Forecast
HK$8.37
2028 Fair Value Forecast
HK$8.66
2029 Fair Value Forecast
HK$9.08
2030 Fair Value Forecast
HK$9.51
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
600276 Stock Forecast Jiangsu Hengrui Medicine Buy 15
¥43.60 Buy/Sell ¥56.49 23.85%
BGNE Stock Forecast BeiGene Buy 6
$164.53 Buy/Sell $285.19 67.14%
1801 Stock Forecast Innovent Biologics Buy 6
HK$40.00 Buy/Sell HK$50.60 27.20%
600196 Stock Forecast Shanghai Fosun Pharmaceutical ... Outperform 16
¥24.76 Buy/Sell ¥33.57 25.77%
600062 Stock Forecast China Resources Double-Crane P... Buy 16
¥21.19 Buy/Sell ¥26.00 8.54%

CSPC Pharmaceutical Group Revenue Forecast for 2023 - 2025 - 2030

In the last two years, CSPC Pharmaceutical Group's Revenue has grown by 24.03%, rising from HK$24.94B to HK$30.94B. For next year, analysts predict Revenue of HK$38.15B, which would mean an increase of 23.32%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Revenue will grow at a rate of 29.47%.

2024 Rev Forecast
HK$38.15B
2025 Rev Forecast
HK$41.21B
2026 Rev Forecast
HK$34.70B
2027 Rev Forecast
HK$36.03B
2028 Rev Forecast
HK$37.43B
2029 Rev Forecast
HK$38.71B
2030 Rev Forecast
HK$40.05B

CSPC Pharmaceutical Group Dividend per Share Forecast for 2023 - 2025 - 2030

In the last two years, CSPC Pharmaceutical Group's Dividend per Share has grown by 72.73%, rising from HK$0.11 to HK$0.19. For next year, analysts predict Dividend per Share of HK$0.20, which would mean an increase of 5.26%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's Dividend per Share will grow at a rate of 5.26%.

2024 DPS Forecast
HK$0.20
2025 DPS Forecast
HK$0.22
2026 DPS Forecast
HK$0.15
2027 DPS Forecast
HK$0.18
2028 DPS Forecast
HK$0.19
2029 DPS Forecast
HK$0.20
2030 DPS Forecast
HK$0.20

CSPC Pharmaceutical Group Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
HK$6.69B
2025 FCF Forecast
HK$6.89B
2026 FCF Forecast
HK$6.78B
2027 FCF Forecast
HK$6.52B
2028 FCF Forecast
HK$7.38B
2029 FCF Forecast
HK$7.66B
2030 FCF Forecast
HK$7.92B

CSPC Pharmaceutical Group EBITDA Forecast for 2023 - 2025 - 2030

CSPC Pharmaceutical Group's EBITDA has grown In the last two years, rising from HK$6.10B to HK$7.61B – a growth of 24.80%. In the next year, analysts believe that EBITDA will reach HK$10.11B – an increase of 32.88%. For the next seven years, experts predict that CSPC Pharmaceutical Group's EBITDA will grow at a rate of 44.33%.

2024 EBITDA Forecast
HK$10.11B
2025 EBITDA Forecast
HK$10.92B
2026 EBITDA Forecast
HK$8.83B
2027 EBITDA Forecast
HK$9.86B
2028 EBITDA Forecast
HK$10.23B
2029 EBITDA Forecast
HK$10.61B
2030 EBITDA Forecast
HK$10.99B

CSPC Pharmaceutical Group EBIT Forecast for 2023 - 2025 - 2030

CSPC Pharmaceutical Group's EBIT has seen impressive growth In the last two years, rising from HK$5.42B to HK$6.76B – a growth of 24.83%. In the next year, analysts believe that EBIT will reach HK$8.81B – an increase of 30.40%. For the next seven years, the forecast is for EBIT to grow by 30.80%.

2024 EBIT Forecast
HK$8.81B
2025 EBIT Forecast
HK$9.32B
2026 EBIT Forecast
HK$7.44B
2027 EBIT Forecast
HK$7.98B
2028 EBIT Forecast
HK$8.26B
2029 EBIT Forecast
HK$8.53B
2030 EBIT Forecast
HK$8.84B

CSPC Pharmaceutical Group EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last four years, CSPC Pharmaceutical Group has seen a decline in its EPS, from HK$0.52 to HK$0.00 – a 100.00% decrease. For next year, analysts predict EPS of HK$0.61, which would mean an increase of 100.00%. Over the next seven years, experts predict that CSPC Pharmaceutical Group's EPS will grow at a rate of 100.00%.

2024 EPS Forecast
HK$0.61
2025 EPS Forecast
HK$0.67
2026 EPS Forecast
HK$0.53
2027 EPS Forecast
HK$0.59
2028 EPS Forecast
HK$0.61
2029 EPS Forecast
HK$0.64
2030 EPS Forecast
HK$0.67